Zydus Lifesciences Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Zydus Lifesciences Ltd is up for a fifth straight session today. The stock is quoting at Rs 924.45, up 0.27% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.33% on the day, quoting at 26163.7. The Sensex is at 85033.17, down 0.48%. Zydus Lifesciences Ltd has slipped around 0.02% in last one month.

Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has slipped around 1.38% in last one month and is currently quoting at 22743.4, up 0.92% on the day. The volume in the stock stood at 1.4 lakh shares today, compared to the daily average of 5.58 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 931.45, up 0.62% on the day. Zydus Lifesciences Ltd is down 7.63% in last one year as compared to a 10.36% jump in NIFTY and a 1.19% jump in the Nifty Pharma index.

The PE of the stock is 19.22 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Bioeq AG (Bioeq), a Swiss biopharmaceutical company, and Zydus Lifesciences (Zydus), an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO?, an interchangeable biosimilar of Lucentis? (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO? has been approved by U.S. Food and Drug Administration (USFDA) on December 18, 2025. This transaction marks an expansion of Zydus' U.S. biosimilar business, following its recent partnership with Formycon AG for a biosimilar of Keytruda? (Pembrolizumab).

Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO? in the U.S. market.

Powered by Capital Market - Live News

Zydus Lifesciences has signed an agreement with Myriad Genetics, a leader in molecular diagnostic testing and precision medicine company. Pursuant to the Agreement, Zydus will be introducing MyRisk? Hereditary Cancer Test, MyChoice? HRD Plus, Homologous Recombination Deficiency (HRD) Test and Prolaris? Prostate Cancer Prognostic Test to patients, clinicians, and healthcare systems across India.

With the increasing incidence of cancers globally, the MyRisk? Test can help people safeguard their health and take precautionary steps and lifestyle changes that can minimise the risk of cancer. In patients suffering from prostate and ovarian cancers, the Prolaris? Test and MyChoice? HRD Plus Test, respectively, can help patients understand the disease progression and inform the right treatment path.

As part of this agreement, Zydus will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics' broadly validated diagnostic platforms, MyRisk? Hereditary Cancer Test, MyChoice? HRD Plus Test for ovarian cancer, and Prolaris? a gene expression Prostate Cancer Prognostic Test.

These tests have been widely adopted in the North America, Europe, and major global cancer centres, and will now empower Indian oncologists with cutting-edge genomic decision-support tools.

Powered by Capital Market - Live News

 Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients. The resubmission has been accepted as a Class I response and as a result, the Company has received January 14, 2026 as the new PDUFA date.

?We appreciate the Agency's partnership and commitment to expeditiously reviewing our NDA resubmission,? said Matt Heck, CEO, Sentynl. ?The acceptance of the application brings us one step closer to a milestone for patients and families who are living with Menkes disease.

Sentynl resubmitted its revised NDA on 14 November 2025 after receiving a complete response letter (CRL) from the FDA on 30 September 2025, which cited observations regarding the manufacturing site's cGMP compliance. The CRL did not cite any other approvability concerns, nor did it identify any deficiencies in CUTX-101's efficacy and safety data, which demonstrate improvement in overall survival for Menkes disease subjects who received early treatment with the therapy.

Powered by Capital Market - Live News